Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 897-913 , October 2006

Diversity of regulatory T cells to control arthritis

References 

  1. Matzinger P. Tolerance, danger, and the extended family. Annual Review of Immunology. 1994;12:991–1045
  2. van Eden W, van dez Zee R, Taams LS, et al. Heat-shock protein T-cell epitopes trigger a spreading regulatory control in a diversified arthritogenic T-cell response. Immunological Reviews. 1998;164:169–174
  3. Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. The Journal of Experimental Medicine. 1993;178(1):27–47
  4. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?. Arthritis and Rheumatism. 1997;40(1):5–18
  5. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307–310
  6. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis and Rheumatism. 1999;42(5):963–970
  7. Morita Y, Yamamura M, Kawashima M, et al. Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis and Rheumatism. 1998;41(9):1669–1676
  8. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis and Rheumatism. 1998;41(12):2108–2116
  9. Roudier J. Association of MHC and rheumatoid arthritis. Association of RA with HLA-DR4: the role of repertoire selection. Arthritis Research. 2000;2(3):217–220
  10. Finnegan A, Mikecz K, Tao P, Glant TT. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. Journal of Immunology. 1999;163(10):5383–5390
  11. Seetharaman R, Mora AL, Nabozny G, et al. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. Journal of Immunology. 1999;163(3):1577–1583
  12. Choy EH, Pitzalis C, Cauli A, et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis and Rheumatism. 1996;39(1):52–56
  13. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New England Journal of Medicine. 2003;349(20):1907–1915
  14. Yudoh K, Matsuno H, Nakazawa F, et al. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis and Rheumatism. 2000;43(3):617–627
  15. Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Annals of the Rheumatic Diseases. 2000;59(4):263–268
  16. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. British Journal of Rheumatology. 1994;33(10):927–931
  17. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proceedings of the National Academy of Sciences of the USA. 1994;91(18):8562–8566
  18. Dolhain RJ, van der Heiden AN, ter Haar NT, et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1996;39(12):1961–1969
  19. McInnes IB, Leung BP, Sturrock RD, et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nature Medicine. 1997;3(2):189–195
  20. Morita Y, Yamamura M, Nishida K, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis and Rheumatism. 1998;41(2):306–314
  21. van Roon JA, Verweij MC, Wijk MW, et al. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis and Rheumatism. 2005;52(6):1700–1710
  22. Mulherin D, Fitzgerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis and Rheumatism. 1996;39(1):115–124
  23. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–361
  24. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends in Immunology. 2006;27(1):17–23
  25. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature Immunology. 2005;6(11):1133–1141
  26. Andersson A, Kokkola R, Wefer J, et al. Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility. Journal of Leukocyte Biology. 2004;76(6):1118–1124
  27. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. Journal of Biological Chemistry. 2003;278(3):1910–1914
  28. Taams LS, van Amelsfort JM, Tiemessen MM, et al. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Human Immunology. 2005;66(3):222–230
  29. van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis and Rheumatism. 2004;50(9):2775–2785
  30. Firestein GS, Alvaro-Gracia JM, Maki R, Alvaro-Garcia JM. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. Journal of Immunology. 1990;144(9):3347–3353
  31. Highton J, Carlisle B, Palmer DG. Changes in the phenotype of monocytes/macrophages and expression of cytokine mRNA in peripheral blood and synovial fluid of patients with rheumatoid arthritis. Clinical and Experimental Immunology. 1995;102(3):541–546
  32. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis and Rheumatism. 1995;38(2):151–160
  33. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis and Rheumatism. 2002;46(12):3143–3150
  34. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annual Review of Immunology. 2001;19:163–196
  35. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis and Rheumatism. 1997;40(2):217–225
  36. Brennan F, Foey A. Cytokine regulation in RA synovial tissue: role of T cell/macrophage contact-dependent interactions. Arthritis Research. 2002;4(supplement 3):S177–S182
  37. van Roon JA, Lafeber FP, Bijlsma JW. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis and Rheumatism. 2001;44(1):3–12
  38. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265(5176):1237–1240
  39. Brownlie RJ, Myers LK, Wooley PH, et al. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis and Rheumatism. 2006;54(3):854–863
  40. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. Journal of Experimental Medicine. 1998;187(5):787–794
  41. Verhoef CM, van Roon JA, Vianen ME, et al. Mutual antagonism of rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance. Annals of the Rheumatic Diseases. 1998;57(5):275–280
  42. van Roon JA, Bijlsma JW. Th2 mediated regulation in RA and the spondyloarthropathies. Annals of the Rheumatic Diseases. 2002;61(11):951–954
  43. Miossec P, Naviliat M, Dupuy d'Angeac A, et al. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis and Rheumatism. 1990;33(8):1180–1187
  44. van Roon JA, van Roy JL, Gmelig-Meyling FH, et al. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis and Rheumatism. 1996;39(5):829–835
  45. van Roon JA, Bijlsma JW, Lafeber FP. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Current Opinion in Investigational Drugs. 2002;3(7):1011–1016
  46. Battaglia M, Gianfrani C, Gregori S, Roncarolo MG. IL-10-producing T regulatory type 1 cells and oral tolerance. Annals of the New York Academy of Science. 2004;1029:142–153
  47. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389(6652):737–742
  48. Cottrez F, Hurst SD, Coffman RL, Groux H. T regulatory cells 1 inhibit a Th2-specific response in vivo. Journal of Immunology. 2000;165(9):4848–4853
  49. Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmunity Reviews. 2005;4(6):351–363
  50. Horwitz DA, Zheng SG, Gray JD, et al. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Seminare in Immunology. 2004;16(2):135–143
  51. Fukaura H, Kent SC, Pietrusewicz MJ, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. The Journal of Clinical Investigation. 1996;98(1):70–77
  52. Appel H, Neure L, Kuhne M, et al. An elevated level of IL-10- and TGFbeta-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Clinical Rheumatology. 2004;23(5):435–440
  53. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 1998;41(2):290–297
  54. Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993;261(5129):1727–1730
  55. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. International Reviews of Immunology. 2005;24(3–4):211–226
  56. van Amelsfort JMR, van Roon JAG, Noordegraaf M, et al. Influence of the inflammatory milieu on the suppressive function of CD4+CD25+ regulatory T cells in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64:521
  57. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. Journal of Experimental Medicine. 1998;188(2):287–296
  58. Taams LS, Smith J, Rustin MH, et al. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. European Journal of Immunology. 2001;31(4):1122–1131
  59. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology. 1995;155(3):1151–1164
  60. Valmori D, Merlo A, Souleimanian NE, et al. A peripheral circulating compartment of natural naive CD4 Tregs. Journal of Clinical Investigation. 2005;115(7):1953–1962
  61. Ruprecht CR, Gattorno M, Ferlito F, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. Journal of Experimental Medicine. 2005;201(11):1793–1803
  62. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. Journal of Experimental Medicine. 2004;200(3):277–285
  63. de Kleer IM, Wedderburn LR, Taams LS, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. Journal of Immunology. 2004;172(10):6435–6443
  64. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunology. 2005;6(4):345–352
  65. Walker MR, Kasprowicz DJ, Gersuk VH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. Journal of Clinical Investigation. 2003;112(9):1437–1443
  66. Morgan ME, van Bilsen JH, Bakker AM, et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Human Immunology. 2005;66(1):13–20
  67. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Reviews Immunology. 2002;2(6):389–400
  68. Dieckmann D, Bruett CH, Ploettner H, et al. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. Journal of Experimental Medicine. 2002;196(2):247–253
  69. Jonuleit H, Schmitt E, Kakirman H, et al. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. Journal of Experimental Medicine. 2002;196(2):255–260
  70. Cederbom L, Hall H, Ivars F. CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. European Journal of Immunology. 2000;30(6):1538–1543
  71. Misra N, Bayry J, Lacroix-Desmazes S, et al. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. Journal of Immunology. 2004;172(8):4676–4680
  72. Morgan ME, Flierman R, van Duivenvoorde LM, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis and Rheumatism. 2005;52(7):2212–2221
  73. Frey O, Petrow PK, Gajda M, et al. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Research and Therapy. 2005;7(2):R291–R301
  74. van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62(2):113–119
  75. George TC, Bilsborough J, Viney JL, Norment AM. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. European Journal of Immunology. 2003;33(2):502–511
  76. Zheng Y, Manzotti CN, Liu M, et al. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. Journal of Immunology. 2004;172(5):2778–2784
  77. Garcia G, Komagata Y, Slavin AJ, et al. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. Journal of Autoimmunity. 1999;13(3):315–324
  78. Sakkas LI, Scanzello C, Johanson N, et al. T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis [see comments]. Clinical and Diagnostic Laboratory Immunology. 1998;5(4):430–437
  79. Prakken BJ, Samodal R, Le TD, et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the USA. 2004;101(12):4228–4233
  80. van Roon JA, van Eden W, van Roy JL, et al. Stimulation of suppressive T cell responses by human but not bacterial 60-kD heat-shock protein in synovial fluid of patients with rheumatoid arthritis. Journal of Clinical Investigation. 1997;100(2):459–463
  81. Beyersdorf N, Gaupp S, Balbach K, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. Journal of Experimental Medicine. 2005;202(3):445–455
  82. Bisikirska B, Colgan J, Luban J, et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. Journal of Clinical Investigation. 2005;115(10):2904–2913
  83. van Maurik A, Herber M, Wood KJ, Jones ND. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. Journal of Immunology. 2002;169(10):5401–5404
  84. Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003;421(6921):388–392
  85. Marshall E. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science. 2006;311(5768):1688–1689
  86. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107(10):3925–3932

PII: S1521-6942(06)00076-3

doi: 10.1016/j.berh.2006.06.006

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 5 , Pages 897-913 , October 2006

Article Tools

* Image Usage & Resolution